Item 1.01
|
Entry into a Material Definitive Agreement.
|
Underwriting Agreement
On February 10, 2021, Adicet Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to a public offering (the “Offering”) of 9,230,770 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at a price to the public of $13.00 per share. In addition, the Company granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 1,344,743 shares. The Company estimates that the net proceeds from the offering will be approximately $112.2 million (or approximately $128.6 million if the underwriters exercise in full their option to purchase additional shares) after deducting the underwriting discount and its estimated offering expenses. The offering is expected to close on February 12, 2021, subject to customary closing conditions.
The Company made certain customary representations, warranties and covenants concerning the Company and the registration statement in the Underwriting Agreement and also agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-229499), filed with the Securities and Exchange Commission (the “Commission”) on February 1, 2019 and declared effective by the Commission on February 12, 2019, as supplemented by a final prospectus supplement dated February 10, 2020, filed on February 11, 2021. This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any of the shares of Common Stock.
The foregoing description of certain terms of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Underwriting Agreement, which is attached as Exhibit 1.1 hereto and is incorporated by reference herein. A copy of the opinion of Goodwin Procter LLP, relating to the legality of the shares of Common Stock, is filed as Exhibit 5.1 hereto and is incorporated by reference herein.
Stock Purchase Agreement
As previously disclosed, concurrently with the execution of the Agreement and Plan of Merger (the “Merger Agreement”), dated April 28, 2020, by and among resTORbio, Inc., Adicet Bio, Inc. and Project Oasis Merger Sub, Inc., the Company entered a funding agreement (the “Funding Agreement”) with certain investors (the “Escrow Investors”) of the Company, pursuant to which the Escrow Investors agreed to fund a certain amount into an escrow account, which will be used to subscribe for shares of our common stock in a concurrent private placement in connection with the Offering, on the same economic conditions (including the price per share) and similar other terms and conditions as the shares being sold in the Offering. In addition, in September 2020, we entered into a Non-Escrow Funding Agreement with certain of our investors (referred to as the “Non-Escrow Investors” and collectively with the Escrow Investors, the “Investors”), pursuant to which the Non-Escrow Investors agreed to subscribe for shares of our Common Stock in a private placement in connection with the Offering, on the same economic conditions (including the price per share) and similar other terms and conditions as the shares being sold in the Offering.
Pursuant to the Funding Agreement and Non-Escrow Funding Agreement, we entered into a stock purchase agreement with the Investors (the “Subscription Agreement”) on February 12, 2020, which requires the Investors to purchase from us, in connection with the Offering in a private placement, $15.0 million of shares of our common stock at a price per share equal to the public offering price, subject to the terms and conditions set forth in the Subscription Agreement. The sale of these shares will not be registered under the Securities Act. The private placement is subject to certain closing conditions, and occurred in an initial closing for the Escrow Investors held simultaneous with the closing of the Offering and a subsequent closing for the Non-Escrow Investors (collectively, the “Closings”). We will receive the full proceeds from the sale and will not pay any underwriting discounts or commissions with respect to the shares of common stock that are sold in the concurrent private placement.